scholarly journals Combining fasting plasma glucose and glycosylated haemoglobin improved the accuracy for detecting patients with diabetes

2003 ◽  
Vol 8 (6) ◽  
pp. 186-186
Author(s):  
L. Leibovici
Keyword(s):  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Glycosylated Haemoglobin ◽  
Fasting Plasma ◽  
Patients With Diabetes

scholarly journals Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies

2019 ◽  
Author(s):  
Lingyun Ma ◽  
Daohuang Luo ◽  
Ting Yang ◽  
Songtao Wu ◽  
Min Li ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Plasma Insulin ◽  
Combined Therapy ◽  
Meta Analysis ◽  
Somatostatin Analogues ◽  
Glycosylated Haemoglobin ◽  
Fasting Plasma ◽  
Fasting Plasma Insulin

Abstract Background: Acromegaly is a rare, chronic and severe disease . Drug therapy including somatostatin analogues , dopamine receptor agonists and growth hormone receptor antagonists are commonly used to treat patients who do not responde to surgery. T he use of combination therapy with PEG and SAs has become more common over the last decade . We performed this study t o accurately evaluate the effect of combination therapy of somatostatin analogues (SAs) with pegvisomant (PEG) on acromegalic patients. Methods: PubMed, EMBASE, The Cochrane Library, and ClinicalTrials.gov were searched for relevant studies. Prospective clinical trials treating acromegaly with the co-administration of SAs and PEG were included. We performed a meta-analysis by using Stata 12.1 . Sensitivity analysis was conducted to explore heterogeneity. Results: Eight studies were included in this meta-analysis. The overall rate of serum insulin-like growth factor 1 (IGF-1) normalization was 75% (95% CI: 50%–93%; I 2 =93.60%). The combination therapy did not significantly change patients’ fasting plasma glucose (ES: 0.011 mmol*L -1 ; 95% CI: − 0.374 to 0.397 mmol*L -1 ; P=0.954) or glycosylated haemoglobin (ES: -0.106%; 95% CI: − 0.302% to 0.089%; P=0.285) while decreasing the fasting plasma insulin (ES: −21.487 pmol*L-1; 95% CI: −35.713 to -7.260 pmol*L-1; P=0.003). Elevation of liver enzyme levels was found in 14% (95% CI: 10% to 19%) of the patients. Conclusions: Combined therapy of SAs and PEG effectively normalized IGF-1 levels in most of the patients whose IGF-1 level was greater than the upper limit of normal after high dose SAs monotherapy. The combination therapy significantly decreased patients’ fasting plasma insulin. However, improved fasting plasma glucose or glycosylated haemoglobin was not found during the combination therapy. Moreover, elevated liver enzyme levels were observed in a small number of patients, which suggests a need for liver function monitoring. Trial registration We have our protocol registered in PROSPERO. (Registration number: CRD42019115549)

Criteria for Screening Diabetes Mellitus Using Serum Fructosamine Level and Fasting Plasma Glucose Level

1993 ◽  
Vol 32 (03) ◽  
pp. 237-240 ◽  
Author(s):  
H. Kiyose ◽  
K. Ito ◽  
T. Iwatsuka ◽  
H. Kawai ◽  
Y. Goto ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Glucose Level ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Plasma Glucose Level ◽  
Fasting Plasma Glucose Level ◽  
Oral Glucose ◽  
Fasting Plasma ◽  
Serum Fructosamine ◽  
Patients With Diabetes

Abstract:A screening method using serum fructosamine level and the fasting plasma glucose level was used for screening patients with diabetes mellitus. The criteria for positive tests recommended by the Japanese Society of Multiphasic Health Testing and Services were evaluated. It was found that levels for the serum fructosamine of 290 µmol/l or higher (or, for the fasting plasma glucose of 110 mg/dl or higher) agreed with the standard oral glucose tolerance test in identifying patients with diabetes mellitus in 96.7% of cases, and the serum fructosamine test was simpler and less expensive.

scholarly journals The Ratio of Estimated Average Glucose to Fasting Plasma Glucose Level Is Superior to Glycated Albumin, Hemoglobin A1c, Fructosamine, and GA/A1c Ratio for Assessingβ-Cell Function in Childhood Diabetes

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Ji Eun Lee ◽  
Ji Woo Lee ◽  
Tatsuyoshi Fujii ◽  
Noriyoshi Fujii ◽  
Jong Weon Choi
Keyword(s):  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Cell Function ◽  
Glycated Albumin ◽  
Model Assessment ◽  
C Peptide ◽  
Fasting Plasma ◽  
Glucose Ratio ◽  
Patients With Diabetes ◽  
Average Glucose

Objective. This study investigated the use of the estimated average glucose to fasting plasma glucose ratio (eAG/fPG ratio) to screen forβ-cell function in pediatric diabetes.Methods. Glycated hemoglobin (HbA1c), glycated albumin (GA), fructosamine, insulin, and C-peptide levels were measured. The ratio of GA to HbA1c (GA/A1c ratio) was calculated, and the homeostasis model assessment ofβ-cell function (HOMA-β) was determined.Results. Median values of C-peptide, insulin, and HOMA-βlevels were significantly higher in patients with an increased eAG/fPG ratio than in those with a decreased eAG/fPG ratio. C-peptide and HOMA-βlevels were more closely correlated with the eAG/fPG ratio than with GA, HbA1c, the GA/A1c ratio, and fructosamine. In contrast, body mass index was significantly associated with GA, GA/A1c ratio, and fructosamine, but not with the eAG/fPG ratio and HbA1c levels. To test the diagnostic accuracies of the eAG/fPG ratio for identifying HOMA-β> 30.0% in patients with type 2 diabetes, the area under the ROC curve of the eAG/fPG ratio was significantly larger than that of the GA/A1c ratio [0.877 (95% CI, 0.780–0.942) versus 0.775 (95% CI, 0.664–0.865),P=0.039].Conclusions. A measurement of the eAG/fPG ratio may provide helpful information for assessingβ-cell function in pediatric patients with diabetes.

scholarly journals Prevalence and Risk Factors of Microalbuminuric in Patients With Diabetes Mellitus and Hypertension in Zhengzhou City, China

2021 ◽  
Author(s):  
Ao Shen ◽  
Lina Wu ◽  
Xiaojun Ma ◽  
Na Jing ◽  
Xiaoxu Ding ◽  
...  
Keyword(s):  
Risk Factors ◽  
Blood Pressure ◽  
Logistic Regression ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Density Lipoprotein ◽  
Diabetic Patients ◽  
Factors Associated ◽  
Fasting Plasma ◽  
Patients With Diabetes

Abstract Background: The prevalence of end-stage renal disease (ESRD) is uprising in the paralleled with the increase of chronic kidney disease (CKD) patients. The objective of this study was to assess the value of macroalbuminuric of kidney disease in diabetic and/or hypertensive patients and the risk factors associated with microalbuminuric. Methods: A total of 3986 patients diagnosed with diabetes and/or hypertension aged 40 years and over was investigated by randomized cluster sampling in the Zhengzhou community and 1453 participants were analyzed in this study. The clinical data were investigated, including the urinary albumin–to-creatinine ratio (ACR), total cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, glycated hemoglobin of HbAlc, fasting plasma glucose, 2-h postprandial plasma, and serum creatinine. The ACR was applied to designate albuminuric. The prevalence of macroalbuminuric was calculated and the risk factors associated with macroalbuminuric were evaluated by stepwise logistic regression. Results: These comprised 612 males and 841 females and the mean age of all patients was 60.6±9.3 years. The prevalence of microalbuminuric and macroalbuminuric was 12.0%, 1.6%, respectively. The prevalence of microalbuminuric in patients with diabetes, hypertension and both diabetes and hypertension were 8.4%, 9.7% and 17.6%, respectively. In subjects with both diabetes and hypertension, the prevalence of microalbuminuric, macroalbuminuric were significantly higher than those who had diabetes or hypertension only. Logistic regression analysis showed microalbuminuric to be significantly associated with systolic blood pressure (OR: 1.92; 95% CI: 1.36-2.72; P < 0.001), diastolic blood pressure (OR: 1.53; 95% CI: 1.02-2.28; P = 0.038), HbA1c (OR: 2.31; 95% CI: 1.64-3.26; P < 0.001). Fasting plasma glucose (OR: 1.79; 95% CI: 1.18-2.71; P = 0.006) and hypertension (OR: 2.45; 95% CI: 1.64-3.65; P < 0.001) were the main independent factors for microalbuminuric in diabetic patients with hypertension or not. Conclusion: The prevalence of microalbuminuric observed in patients diagnosed with diabetes and/or hypertension aged over 40 reached up to 12.0% in the Zhengzhou community. Microalbuminuric was strongly associated with systolic blood pressure, diastolic blood pressure and HbA1c. Fasting plasma glucose and hypertension were the main independent factors for microalbuminuric in diabetic patients with hypertension or not.

Sign in / Sign up

Export Citation Format

Share Document